Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of “Buy” by Brokerages

Shares of Rezolute, Inc. (NASDAQ:RZLT) have been given a consensus rating of “Buy” by the seven ratings firms that are presently covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have covered the stock in the last year is $10.14.

Several research analysts have commented on the company. BTIG Research assumed coverage on Rezolute in a report on Wednesday, July 17th. They set a “buy” rating and a $13.00 target price on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $7.00 target price on shares of Rezolute in a report on Thursday, April 18th. HC Wainwright reissued a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a research note on Wednesday, May 22nd. Jonestrading initiated coverage on Rezolute in a research note on Thursday, April 18th. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, Craig Hallum initiated coverage on Rezolute in a research note on Tuesday, June 4th. They issued a “buy” rating and a $14.00 price objective on the stock.

Rezolute Price Performance

NASDAQ RZLT opened at $4.68 on Wednesday. Rezolute has a twelve month low of $0.72 and a twelve month high of $6.10. The company has a market cap of $187.81 million, a price-to-earnings ratio of -4.11 and a beta of 1.20. The business’s fifty day moving average is $4.30 and its 200 day moving average is $2.80.

Rezolute (NASDAQ:RZLT) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.34) earnings per share for the quarter, meeting the consensus estimate of ($0.34). On average, research analysts anticipate that Rezolute will post -1.15 earnings per share for the current fiscal year.

Insider Transactions at Rezolute

In other Rezolute news, CFO Daron Evans bought 40,000 shares of the business’s stock in a transaction dated Friday, June 14th. The shares were purchased at an average price of $4.04 per share, for a total transaction of $161,600.00. Following the purchase, the chief financial officer now directly owns 40,000 shares of the company’s stock, valued at $161,600. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Insiders have acquired 57,124 shares of company stock worth $220,314 in the last 90 days. Insiders own 20.80% of the company’s stock.

Institutional Investors Weigh In On Rezolute

Several institutional investors have recently made changes to their positions in the stock. Rosalind Advisors Inc. lifted its position in shares of Rezolute by 25.0% during the second quarter. Rosalind Advisors Inc. now owns 250,000 shares of the company’s stock worth $1,075,000 after acquiring an additional 50,000 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Rezolute in the first quarter worth $37,000. Affinity Asset Advisors LLC bought a new position in shares of Rezolute in the first quarter worth $4,080,000. Acadian Asset Management LLC bought a new position in shares of Rezolute in the first quarter worth $229,000. Finally, Vanguard Group Inc. increased its holdings in shares of Rezolute by 10.4% in the first quarter. Vanguard Group Inc. now owns 1,553,352 shares of the company’s stock worth $3,961,000 after purchasing an additional 145,700 shares during the period. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.